446 related articles for article (PubMed ID: 33417876)
1. Comparison of the Efficacy and Safety of Sacubitril/Valsartan versus Ramipril in Patients With ST-Segment Elevation Myocardial Infarction.
Rezq A; Saad M; El Nozahi M
Am J Cardiol; 2021 Mar; 143():7-13. PubMed ID: 33417876
[TBL] [Abstract][Full Text] [Related]
2. Impact of Sacubitril/Valsartan Compared With Ramipril on Cardiac Structure and Function After Acute Myocardial Infarction: The PARADISE-MI Echocardiographic Substudy.
Shah AM; Claggett B; Prasad N; Li G; Volquez M; Jering K; Cikes M; Kovacs A; Mullens W; Nicolau JC; Køber L; van der Meer P; Jhund PS; Ibram G; Lefkowitz M; Zhou Y; Solomon SD; Pfeffer MA
Circulation; 2022 Oct; 146(14):1067-1081. PubMed ID: 36082663
[TBL] [Abstract][Full Text] [Related]
3. Angiotensin Receptor-Neprilysin Inhibition in Patients With STEMI vs NSTEMI.
Mann DL; Nicolas J; Claggett B; Miao ZM; Granger CB; Kerkar P; Køber L; Lewis EF; McMurray JJV; Maggioni AP; Núñez J; Ntsekhe M; Rouleau JL; Sim D; Solomon SD; Steg PG; van der Meer P; Braunwald E; Pfeffer MA; Mehran R
J Am Coll Cardiol; 2024 Mar; 83(9):904-914. PubMed ID: 38418004
[TBL] [Abstract][Full Text] [Related]
4. Angiotensin Receptor-Neprilysin Inhibition in Acute Myocardial Infarction.
Pfeffer MA; Claggett B; Lewis EF; Granger CB; Køber L; Maggioni AP; Mann DL; McMurray JJV; Rouleau JL; Solomon SD; Steg PG; Berwanger O; Cikes M; De Pasquale CG; East C; Fernandez A; Jering K; Landmesser U; Mehran R; Merkely B; Vaghaiwalla Mody F; Petrie MC; Petrov I; Schou M; Senni M; Sim D; van der Meer P; Lefkowitz M; Zhou Y; Gong J; Braunwald E;
N Engl J Med; 2021 Nov; 385(20):1845-1855. PubMed ID: 34758252
[TBL] [Abstract][Full Text] [Related]
5. The Effects of Angiotensin Receptor-Neprilysin Inhibition on Major Coronary Events in Patients With Acute Myocardial Infarction: Insights From the PARADISE-MI Trial.
Mehran R; Steg PG; Pfeffer MA; Jering K; Claggett B; Lewis EF; Granger C; Køber L; Maggioni A; Mann DL; McMurray JJV; Rouleau JL; Solomon SD; Ducrocq G; Berwanger O; De Pasquale CG; Landmesser U; Petrie M; Leng DSK; van der Meer P; Lefkowitz M; Zhou Y; Braunwald E
Circulation; 2022 Dec; 146(23):1749-1757. PubMed ID: 36321459
[TBL] [Abstract][Full Text] [Related]
6. Prospective ARNI vs. ACE inhibitor trial to DetermIne Superiority in reducing heart failure Events after Myocardial Infarction (PARADISE-MI): design and baseline characteristics.
Jering KS; Claggett B; Pfeffer MA; Granger C; Køber L; Lewis EF; Maggioni AP; Mann D; McMurray JJV; Rouleau JL; Solomon SD; Steg PG; van der Meer P; Wernsing M; Carter K; Guo W; Zhou Y; Lefkowitz M; Gong J; Wang Y; Merkely B; Macin SM; Shah U; Nicolau JC; Braunwald E
Eur J Heart Fail; 2021 Jun; 23(6):1040-1048. PubMed ID: 33847047
[TBL] [Abstract][Full Text] [Related]
7. Rationale and design of a multi-center, prospective randomized controlled trial on the effects of sacubitril-valsartan versus enalapril on left ventricular remodeling in ST-elevation myocardial infarction: The PERI-STEMI study.
Diao K; Wang D; Chen Z; Wu X; Ma M; Zhu Y; Zhang L; Wang H; Wang M; He S; Li C; Deng Q; Yan T; Wu T; Tang L; Huang B; Sun J; He Y
Clin Cardiol; 2021 Dec; 44(12):1709-1717. PubMed ID: 34668596
[TBL] [Abstract][Full Text] [Related]
8. The Value of Sacubitril/Valsartan in Acute Anterior Wall ST-Segment Elevation Myocardial Infarction before Emergency Percutaneous Coronary Intervention.
Lin G; Chen W; Wu M; Dai C; Xu K
Cardiology; 2022; 147(5-6):479-485. PubMed ID: 36198259
[TBL] [Abstract][Full Text] [Related]
9. Angiotensin Receptor-Neprilysin Inhibitor in Acute Myocardial Infarction.
Pathak P
J Assoc Physicians India; 2022 Apr; 70(4):11-12. PubMed ID: 35443387
[TBL] [Abstract][Full Text] [Related]
10. Influence of Ejection Fraction on Outcomes and Efficacy of Sacubitril/Valsartan (LCZ696) in Heart Failure with Reduced Ejection Fraction: The Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure (PARADIGM-HF) Trial.
Solomon SD; Claggett B; Desai AS; Packer M; Zile M; Swedberg K; Rouleau JL; Shi VC; Starling RC; Kozan Ö; Dukat A; Lefkowitz MP; McMurray JJ
Circ Heart Fail; 2016 Mar; 9(3):e002744. PubMed ID: 26915374
[TBL] [Abstract][Full Text] [Related]
11. Sacubitril/Valsartan Across the Spectrum of Ejection Fraction in Heart Failure.
Solomon SD; Vaduganathan M; L Claggett B; Packer M; Zile M; Swedberg K; Rouleau J; A Pfeffer M; Desai A; Lund LH; Kober L; Anand I; Sweitzer N; Linssen G; Merkely B; Luis Arango J; Vinereanu D; Chen CH; Senni M; Sibulo A; Boytsov S; Shi V; Rizkala A; Lefkowitz M; McMurray JJV
Circulation; 2020 Feb; 141(5):352-361. PubMed ID: 31736342
[TBL] [Abstract][Full Text] [Related]
12. Sacubitril/valsartan versus ramipril for patients with acute myocardial infarction: win-ratio analysis of the PARADISE-MI trial.
Berwanger O; Pfeffer M; Claggett B; Jering KS; Maggioni AP; Steg PG; Mehran R; Lewis EF; Zhou Y; van der Meer P; De Pasquale C; Merkely B; Filippatos G; McMurray JJV; Granger CB; Solomon SD; Braunwald E
Eur J Heart Fail; 2022 Oct; 24(10):1918-1927. PubMed ID: 36054480
[TBL] [Abstract][Full Text] [Related]
13. Angiotensin-Neprilysin Inhibition in Acute Decompensated Heart Failure.
Velazquez EJ; Morrow DA; DeVore AD; Duffy CI; Ambrosy AP; McCague K; Rocha R; Braunwald E;
N Engl J Med; 2019 Feb; 380(6):539-548. PubMed ID: 30415601
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of sacubitril/valsartan compared with enalapril in patients with chronic heart failure and reduced ejection fraction: Results from PARADIGM-HF India sub-study.
Jain AR; Aggarwal RK; Rao NS; Billa G; Kumar S
Indian Heart J; 2020; 72(6):535-540. PubMed ID: 33357641
[TBL] [Abstract][Full Text] [Related]
15. SAcubitril/valsartan versus ramipril in patients with ST-segment Elevation Myocardial Infarction and cardiogenic SHOCK (SAVE-SHOCK): a pilot randomized controlled trial.
Rezq A; Saad M; El Nozahi M
Am J Cardiovasc Dis; 2021; 11(6):734-742. PubMed ID: 35116186
[TBL] [Abstract][Full Text] [Related]
16. Initiation of Angiotensin-Neprilysin Inhibition After Acute Decompensated Heart Failure: Secondary Analysis of the Open-label Extension of the PIONEER-HF Trial.
DeVore AD; Braunwald E; Morrow DA; Duffy CI; Ambrosy AP; Chakraborty H; McCague K; Rocha R; Velazquez EJ;
JAMA Cardiol; 2020 Feb; 5(2):202-207. PubMed ID: 31825471
[TBL] [Abstract][Full Text] [Related]
17. Sacubitril/valsartan compared to ramipril in high-risk post-myocardial infarction patients stratified according to use of mineralocorticoid receptor antagonists: Insight from the PARADISE MI trial.
Schou M; Claggett B; Miao ZM; Fernandez A; Filippatos G; Granger C; Jering K; Maggioni AP; McCausland F; Villota JN; Rouleau JL; Mody FV; van der Meer P; Vinereanu D; McGrath M; Zhou Y; Mann DL; Solomon SD; Steg PG; Braunwald E; McMurray JJV; Pfeffer MA; Køber L
Eur J Heart Fail; 2024 Jan; 26(1):130-139. PubMed ID: 37933184
[TBL] [Abstract][Full Text] [Related]
18. Effects of Sacubitril/Valsartan on Biomarkers of Extracellular Matrix Regulation in Patients With HFrEF.
Zile MR; O'Meara E; Claggett B; Prescott MF; Solomon SD; Swedberg K; Packer M; McMurray JJV; Shi V; Lefkowitz M; Rouleau J
J Am Coll Cardiol; 2019 Feb; 73(7):795-806. PubMed ID: 30784673
[TBL] [Abstract][Full Text] [Related]
19. The initial timing and dosage pattern of sacubitril/valsartan in patients with acute myocardial infarction undergoing percutaneous coronary intervention.
Gu J; Wang Y; Wang CQ; Zhang JF
Eur J Intern Med; 2023 Jun; 112():62-69. PubMed ID: 36990878
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic effects and safety of early use of sacubitril/valsartan after acute myocardial infarction: a systematic review and meta-analysis.
Zhang L; Yan K; Zhao H; Shou Y; Chen T; Chen J
Ann Palliat Med; 2022 Mar; 11(3):1017-1027. PubMed ID: 35365031
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
